Tag: Antibody
AstraZeneca gets CDSCO nod for Datopotamab Deruxtecan to treat Metastatic Breast...
The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at a rapid pace and marks its second antibody–drug conjugate (ADC) approval in India
Lupin receives positive CHMP opinion for Biosimilar Ranibizumab
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A)
Aurigene showcases explainable AI and physics-based molecular design at Discovery and...
Combining XAI, molecular dynamics, and a 12-billion-compound universe, Aurigene.AI delivers breakthroughs from kinase inhibitors to bispecifics — all backed by lab validation
Philogen completes patient enrollment of Phase III FIBROSARC trial in soft...
All ongoing Fibromun trials are expected remain on track with their expected timelines
Ichnos Glenmark Innovation’s drug for relapsed multiple myeloma demonstrates postive tolerability...
Company's first presentation of data from Phase 1 study of the Trispecific ISB 2001 showed an overall response rate (ORR) of 75% in Relapsed/Refractory Multiple Myeloma
Jubilant Biosys to expand its footprint in Europe, add drug discovery...
Through a series of collaborative and acquisition deals, company aims to develop a unique delivery model tailored for its customers
China’s surge in antibody-drug conjugates positions it as key oncology market,...
ADCs have become a focal point in oncology due to their ability to selectively target cancer cells, resulting in reduced off-target side effects.
Bhushan Akshikar appointed as OPPI President
Bhushan is the Vice President & Managing Director of GSK (GlaxoSmithKline Pharmaceuticals) India
IIT Madras researchers develop database on Coronavirus antibodies
‘Ab-CoV’ can be a vital resource for researchers to develop therapeutic strategies against new variants of Coronaviruses by facilitating antibody engineering and immune escape analysis
Exclusive: Antibody against multiple emerging SARS-CoV-2 variants
A broadly neutralizing highly potent human monoclonal antibody developed in India against multiple emerging SARS-CoV-2 variants